Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127307281 | 12730728 | 1 | I | 20160904 | 20160910 | 20160910 | EXP | ES-AMGEN-ESPSP2016120446 | AMGEN | MARTINEZ L. SERIOUS MEDICINES ERRORS RELATED TO ANTINEOPLASIC AND SUPPORTIVE TREATMENT IN CANCER PATIENTS. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2014;21(SUPPL 1):A167-A168 | 0.00 | A | M | Y | 0.00000 | 20160910 | OT | ES | ES |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127307281 | 12730728 | 1 | PS | filgrastim | FILGRASTIM | 1 | Unknown | UNK | U | 103353 | UNKNOWN FORMULATION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127307281 | 12730728 | 1 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127307281 | 12730728 | HO |
| 127307281 | 12730728 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127307281 | 12730728 | Drug dispensing error | |
| 127307281 | 12730728 | Drug dose omission | |
| 127307281 | 12730728 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |